Clinical Study On Treatment Of Chronic Prostatitis/Chronic Pelvic Pain Syndromes By Chuanshentong And Alpha-1A Receptor Blockader

Objective:To evaluate the efficacy that Chuanshentong and alpha-1A receptor blockader treat Chronic Prostatitis/Chronic Pelvic Pain Syndromes with syndrome types of Xueyu.Methods:The patients who would be consistent with the inclusion criteria were divided into two groups randomly:Chuanshentong group(n=30),injected Chuanshentong injection into the prostate by perineal and took tamsulosin hydrochloride release capsules for 18 days. Control group(n=30),took tamsulosin hydrochloride release capsules for 18 days.Every group was examined with the National Institutes of Health chronic prostatitis symptom index(NIH-CPSI),chronic prostatitis Traditional Chinese Medicine(TCM) score,maximum urinary flow rate and residual urine volume at pre-treatment,post-treatment and one month drug off-application.These results were statistically analyzed.Result:1.The efficacy of Chuanshentong group were better than the efficacy of control group at post-treatment and one month drug off-application.The efficacy of Chuanshentong group at one month drug off-application was not significantly changed compared with post-treatment.But the efficacy of Control group was decreased significantly.2.The Chuanshentong group and the control group had able to improve the patient's NIH-CPSI total score,pain score,urinary tract symptom score,quality of life score,TCM score, maximum flow rate,residual urine volume at post-treatment and one month drug off-application.However,Chuanshentong group to improve the situation was better than the control group.3.It was no significantly change in the NIH-CPSI total score,pain score, urinary tract symptom score,quality of life score,TCM score,maximum urinary flow rate, residual urine volume of Chuanshentong group between the period of one month drug off-application and post-treatment,but the control group was aggravation.Conclusion:It is a effective way to treat CP/CPPS with chuanshentong and alpha-1A receptor blockader.It has unique advantages to improve the clinical symptoms,quality of life and on lower urinary tract obstruction,and can effectively delay or reduce the pathogenetic condition relapse.